Ozone therapy for high-grade glioma: an overview

被引:5
|
作者
Yanchu, Li [1 ]
Rong, Pu [2 ]
Rong, Cao [1 ]
Li, Zhang [1 ]
Xiaoyan, Yang [3 ]
Feng, Wang [1 ]
机构
[1] Sichuan Univ, Head & Neck Oncol Ward, West China Hosp, Chengdu, Peoples R China
[2] Chengdu Fuxing Hosp, Oncol Dept, Chengdu, Peoples R China
[3] Sichuan Univ, Radiat Therapy Dept, West China Hosp, Chengdu, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
ozone; high-grade glioma; therapy; chemotherapy; radiation therapy; OXIDATIVE STRESS; CHROMOSOME BREAKAGE; IN-VITRO; CANCER; GLIOBLASTOMA; GROWTH;
D O I
10.3389/fonc.2023.1161206
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-grade gliomas (grades III and IV) are highly malignant and aggressive brain tumors that present significant treatment challenges. Despite advances in surgery, chemotherapy, and radiation therapy, the prognosis for patients with glioma remains poor, with a median overall survival (mOS) range of 9-12 months. Therefore, exploring new and effective therapeutic strategies to improve glioma prognosis is of utmost importance and ozone therapy is a viable option. Ozone therapy has been used in various cancers, such as colon, breast, and lung, yielding significant results in preclinical studies and clinical trials. Only a few studies have been conducted on gliomas. Furthermore, since the metabolism of brain cells involves aerobic glycolysis, ozone therapy may improve the oxygen condition and enhance glioma radiation treatment. However, understanding the correct ozone dosage and optimal time of administration remains challenging. Herein, we hypothesize that ozone therapy should be more effective in gliomas compared with other tumors. This study provides an overview of the use of ozone therapy in high-grade glioma, including mechanisms of action, preclinical data, and clinical evidence.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Bevacizumab for the treatment of high-grade glioma
    Khasraw, Mustafa
    Simeonovic, Marcelle
    Grommes, Christian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (08) : 1101 - 1111
  • [32] Bevacizumab at recurrence in high-grade glioma
    Andrea Salmaggi
    Paola Gaviani
    Andrea Botturi
    Elena Lamperti
    Giorgia Simonetti
    Daniela Ferrari
    Antonio Silvani
    Neurological Sciences, 2011, 32 : 251 - 253
  • [33] Cellular immunotherapy for high-grade glioma
    Chow, Kevin K. H.
    Gottschalk, Stephen
    IMMUNOTHERAPY, 2011, 3 (03) : 423 - 434
  • [34] Temozolomide for recurrent high-grade glioma
    Macdonald, DR
    SEMINARS IN ONCOLOGY, 2001, 28 (04) : 3 - 12
  • [35] Cognition in survivors of high-grade glioma
    Cairncross, JG
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 3210 - 3211
  • [36] Healthcare Costs for High-grade Glioma
    Liu, Yang
    Tyler, Evan
    Lustick, Martin
    Klein, David
    Walter, Kevin A.
    ANTICANCER RESEARCH, 2019, 39 (03) : 1375 - 1381
  • [37] Antiangiogenic therapies for high-grade glioma
    Andrew D. Norden
    Jan Drappatz
    Patrick Y. Wen
    Nature Reviews Neurology, 2009, 5 : 610 - 620
  • [38] Modification of MRI pattern of high-grade glioma pseudoprogression in regorafenib therapy
    Mansour, Mariam
    Vitale, Valerio
    Lombardi, Giuseppe
    Riva, Giulio
    Pancheri, Francesca
    Zanusso, Mariano
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2022, 66 (03) : 414 - 418
  • [39] Anti-Angiogenic Therapy in High-Grade Glioma (Treatment and Toxicity)
    Jennie Taylor
    Elizabeth R. Gerstner
    Current Treatment Options in Neurology, 2013, 15 : 328 - 337
  • [40] Anti-Angiogenic Therapy in High-Grade Glioma (Treatment and Toxicity)
    Taylor, Jennie
    Gerstner, Elizabeth R.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2013, 15 (03) : 328 - 337